⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone

Official Title: A Phase II Surgical Trial Of Intralesional Resection Of Low-Grade Intracompartmental Chondrosarcoma Of Bone

Study ID: NCT00096213

Conditions

Sarcoma

Study Description

Brief Summary: RATIONALE: Intralesional resection is a less invasive type of surgery for chondrosarcoma of the bone and may have fewer side effects and improve recovery. PURPOSE: This phase II trial is studying how well intralesional resection works in treating patients with low-grade chondrosarcoma of the bone.

Detailed Description: OBJECTIVES: * Determine the probability of local complications (e.g., fracture, nerve palsy, deep venous thrombosis, unexpected rehospitalization, unanticipated reoperation, or death within 2 years) in patients with suspected low-grade intracompartmental chondrosarcoma of the bone undergoing intralesional resection. * Determine the 5-year probability of local recurrence and development of metastatic disease in patients undergoing this procedure. * Determine the impact of musculoskeletal tumor reconstruction on the functional status of patients undergoing this procedure. OUTLINE: This is a multicenter study. Patients undergo intralesional resection (curettage with high-speed burr). Patients then receive local adjuvant treatment comprising liquid nitrogen, phenol, alcohol, or argon beam to the excision site. The bone cavity is then filled with either polymethyacrylate cement or a bone graft (allograft or homograft). Patients may also have a metal plate installed at the wound site. Patients are followed every 3 months for 1 year and then every 6 months for 4 years. PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study within 30-60 months.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

University of Colorado Cancer Center at University of Colorado Health Sciences Center, Aurora, Colorado, United States

University of Florida Shands Cancer Center, Gainesville, Florida, United States

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States

University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, United States

Akron City Hospital, Akron, Ohio, United States

Oregon Health & Science University Cancer Institute, Portland, Oregon, United States

Presbyterian Hospital of Dallas, Dallas, Texas, United States

Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States

St. Joseph Cancer Center, Bellingham, Washington, United States

Olympic Hematology and Oncology, Bremerton, Washington, United States

Skagit Valley Hospital Cancer Care Center, Mt. Vernon, Washington, United States

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Harborview Medical Center, Seattle, Washington, United States

Minor and James Medical, PLLC, Seattle, Washington, United States

Group Health Central Hospital, Seattle, Washington, United States

Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle, Washington, United States

Polyclinic First Hill, Seattle, Washington, United States

University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States

North Puget Oncology at United General Hospital, Sedro-Wooley, Washington, United States

Cancer Care Northwest - Spokane South, Spokane, Washington, United States

Wenatchee Valley Medical Center, Wenatchee, Washington, United States

Contact Details

Name: R. Lor Randall, MD, FACS

Affiliation: University of Utah

Role: STUDY_CHAIR

Name: Janet S. Biermann, MD

Affiliation: University of Michigan Rogel Cancer Center

Role: STUDY_CHAIR

Name: Edward Cheng, MD

Affiliation: Masonic Cancer Center, University of Minnesota

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: